CLIP Inducing Agent Protects Mucosal Cells From Autoimmune Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases and mucosal disorders, such as Crohn's disease and ulcerative colitis, often involve eliminating or inhibiting B cells without understanding the underlying mechanisms, and there is a need for effective methods to protect mucosal cells from MHC-mediated cell death.
Innovation Solution
Administering a CLIP inducing agent, such as exogenous CLIP or a CLIP expression vector, to promote CLIP expression on mucosal cells, thereby protecting them from MHC class I or II mediated cell death and reducing autoimmune disease severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If current therapies eliminate or inhibit B cells to treat autoimmune diseases, then autoimmune responses are reduced, but the underlying mechanisms are not understood and mucosal cells remain vulnerable to MHC-mediated cell death
Solution Approach 1:
The patent introduces CLIP peptide as an intermediary substance that mediates protection between MHC class II molecules and mucosal cells. CLIP binds to MHC class II molecules and prevents them from mediating cell death, thereby protecting mucosal cells while allowing the immune system to function. This intermediary approach resolves the contradiction by providing a specific molecular mechanism that protects cells without requiring broad immunosuppression.
Solution Approach 2:
The patent extracts and utilizes the protective fragment CLIP from the invariant chain molecule. By isolating this specific protective component and administering it exogenously, the therapy provides targeted protection to mucosal cells without affecting other aspects of the immune response, thus reducing harmful autoimmune factors while maintaining cell reliability.
2Reliability
If CLIP is placed on mucosal cell surface, then protection from MHC-mediated cell death is achieved, but the mechanism of action needs to be elucidated
Solution Approach 1:
The patent utilizes the natural protective function of CLIP that cells already possess endogenously. By administering exogenous CLIP, the therapy allows cells to self-protect through their inherent CLIP-MHC interaction mechanism, rather than requiring external intervention. This self-service approach achieves cell survival while the mechanism is revealed through the restoration of normal cellular protective pathways.
3Reliability
If exogenous CLIP or CLIP expression vector is administered, then CLIP expression on mucosal cells is promoted and cell protection is enhanced, but treatment complexity increases
Solution Approach 1:
The patent employs exogenous CLIP peptide, a small, simple, and easily synthesized molecule, as the therapeutic agent. This disposable-like approach uses a simple peptide that can be administered repeatedly without requiring complex delivery systems or long-term infrastructure, thereby enhancing cell protection while minimizing treatment complexity.
Data Source
AI summary
The disclosure relates to methods for treating disorders of the mucosal tract such as the gastrointestinal system by targeting CLIP molecules. The methods are based on that CLIP in the groove of MHC class I or II molecules of the cells lining the mucosal surfaces of the body, such as the gastrointestinal tract, provides protection from MHC Class II or MHC class I mediated cell death, and therefore are useful for treating, inhibiting the development of a multitude of illnesses and conditions of the mucosal tract, including autoimmune disease.